3,318 research outputs found
Role of genetic research in the prevention of life-threatening rhythm and cardiac conduction disorders in young people
According to epidemiological studies, in Russia there is a tendency towards an increase in sudden cardiac death (SCD), including among young workingage people. The leading mechanism for SCD in young patients, including those with undifferentiated connective tissue disease, is recognized as rhythm and conduction disorders. At the same time, the most tragic cases are the first and only manifestation of SCD in children and young people without structural heart disease. The article presents a brief analysis of the genetic causes of life-threatening rhythm and conduction disorders in young people, as well as a generalization of the modern possibilities of a personalized diagnostic approach from the standpoint of early cardiovascular prevention. Timely genetic diagnosis of SCD risk makes it possible to identify a predisposition to the development of a fatal event long before its occurrence, which contributes to the timely implementation of preventive measures within a high cardiovascular risk strategy and secondary prevention, maintaining working capacity, creative and social activity of young patients, and improving the quality of life
Practical efficacy and safety of Konsilar D24 in patients with hypertension: data from the KONSONANS program
Aim. In practice, to evaluate the efficacy, safety and long-term adherence to therapy with a fixed-dose combination of ramipril/indapamide (Konsilar-D24) in patients with grade 1-2 hypertension (HTN) who have not achieved blood pressure (BP) control with prior therapy or have not taken antihypertensive therapy.Material and methods. This multicenter open-label observational program included 524 patients with grade 1-2 HTN who did not take antihypertensive therapy or did not reach the target BP level with mono or dual antihypertensive therapy, as well as patients shifted to Konsilar-D24 therapy no later than two weeks before the start of the program. All patients signed a written informed consent to participate in the program. The safety analysis set includes all patients who have taken at least one dose of a fixed-dose combination of ramipril/indapamide and have visited physician at least once during the program. The effectiveness analysis set included all patients in the safety population who completed the study in accordance with protocol (n=511). Clinical systolic blood pressure (SBP), diastolic BP (DBP) and heart rate were assessed at baseline, as well as at 0,5, 1, 3 and 6 months of treatment. A post hoc subgroup analysis of changes in BP and heart rate was performed depending on age, sex and baseline body mass index.Results. The fixed-dose combination of ramipril with indapamide significantly reduced SBP and DBP after 2-week treatment (-20,9Β±10,1 mm Hg; pConclusion. Despite the limitations inherent in observational studies, the KONSONANS program has demonstrated high efficacy and safety of fixed-dose combination of ramipril/indapamide taken once a day in hypertensive patients. Ramipril/indapamide fixed-dose combination therapy significantly improved BP control and achieved even lower individual target BP levels in the majority of hypertensive patients
ΠΠΎΠ²ΡΠΎΡΠ½ΡΠ΅ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΈ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΠ΅ΠΉ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ: ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅
An analysis of medical documents and morphological examination of resected lung samples was done in 25 children had been operated for repeated pneumonias. All the children (100 %) were diagnosed undifferentiated connective tissue dysplasia (CTD) with marked clinical features. Morphological substrate of the repeated pneumonias was various defects of the lung growth. The results showed that the CTD as a genetic systemic pathology provided repeated pneumonias in structural abnormalities of the lungs. This fact should be taken into account in the diagnostic work-up.ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ ΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ΅Π·Π΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΡΠ°ΡΡΠΊΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
Ρ 25 Π΄Π΅ΡΠ΅ΠΉ, ΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΉ. Π£ 100% Π΄Π΅ΡΠ΅ΠΉ Π²ΠΎ Π²ΡΠ΅ΠΌΡ ΠΎΡΠΌΠΎΡΡΠ° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π° Π½Π΅Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΡ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ (ΠΠ‘Π’) Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΌΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΡΠ±ΡΡΡΠ°ΡΠΎΠΌ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΉ ΡΠ²ΠΈΠ»ΠΈΡΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ ΠΏΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ, ΡΡΠΎ ΠΠ‘Π’ ΠΊΠ°ΠΊ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈ Π΄Π΅ΡΠ΅ΡΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΠΉ ΠΏΡΠΎΡΠ΅ΡΡ ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»Π°Π³Π°Π΅Ρ ΠΊ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΉ Π½Π° ΡΠΎΠ½Π΅ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ
Π°Π½ΠΎΠΌΠ°Π»ΠΈΠΉ Π»Π΅Π³ΠΊΠΈΡ
, ΡΡΠΎ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΡΡΠΈΡΡΠ²Π°ΡΡ Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠ΅
Π‘ΠΏΠΎΠ½ΡΠ°Π½Π½ΡΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΡΠΎΡΠ°ΠΊΡ ΠΈ Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΡ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ: ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
Summary. To evaluate a role of polymorphic variants of alpha1-antitrypsin (AAT) genes and matrix metalloproteinase (MMP) genes for heritable susceptibility to bullous emphysema and primary spontaneous pneumothorax (PSP) in patients with connective tissue dysplasia (CTD), we analyzed polymorphic loci of PIZ (Glu342Lys), PIS (Glu264Val), MMP1 (1607insG), MMP9 (C-1562T), MMP12 (A-82G), and TIMP1 (Π‘536Π’) genes and studied serum AAT concentration. We did not find any significant difference between prevalence of the Z- and S-mutations of PI gene and serum AAT concentration between groups. MMP1 homozygous GG/GG genotype was associated with risk of PSP development (odds ratio (OR), 2.23; 95 % confidence interval (Π‘I): 1.34β3.73), MMP1 GG allele (OR, 2.27; 95 % CI: 1.61β3.20), MMP9 heterozigous Π‘/Π’ genotype (OR, 2.43; 95%CI: 1.37β4.31), MMP9 homozygous Π’/Π’ genotype (OR, 4.38; 95 % CI: 1.12β20.00), MMP9 T allele (OR, 2.78; 95 % CI: 1.74β4.46). All alleles and genotypes were found significantly more often in patients with signs of CTD. No statistically significant difference for any polymorphic locus of the studied genes was seen between prevalence of allele variants in patients with PSP but not having CTD and in population sample.Π Π΅Π·ΡΠΌΠ΅. Π‘ ΡΠ΅Π»ΡΡ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠΎΠ»ΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π³Π΅Π½ΠΎΠ² Π°Π»ΡΡΠ°1-Π°Π½ΡΠΈΡΡΠΈΠΏΡΠΈΠ½Π° (Ξ±1-ΠΠ’) ΠΈ ΠΌΠ°ΡΡΠΈΠΊΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π°Π· (MMP) Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π±ΡΠ»Π»Π΅Π·Π½ΠΎΠΉ ΡΠΌΡΠΈΠ·Π΅ΠΌΡ ΠΈ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΏΠΎΠ½ΡΠ°Π½Π½ΠΎΠ³ΠΎ ΠΏΠ½Π΅Π²ΠΌΠΎΡΠΎΡΠ°ΠΊΡΠ° (Π‘Π) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΠ΅ΠΉ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ (ΠΠ‘Π’) ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΡ
Π»ΠΎΠΊΡΡΠΎΠ² PIZ (Glu342Lys), PIS (Glu264Val), MMP1 (1607insG), MMP9 (C-1562T), MMP12 (A-82G), TIMP1 (Π‘536Π’) ΠΈ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Ξ±1-ΠΠ’ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π½Π΅ΡΠ΅Π»ΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ. ΠΠ½Π°ΡΠΈΠΌΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΡΠ°ΡΡΠΎΡΡ Z- ΠΈ S-ΠΌΡΡΠ°ΡΠΈΠΉ Π³Π΅Π½Π° PI ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Ξ±1-ΠΠ’ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ Π½Π΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ. ΠΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ Ρ ΡΠΈΡΠΊΠΎΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ Π‘Π Π²ΡΡΠ²Π»Π΅Π½Ρ Π΄Π»Ρ Π³ΠΎΠΌΠΎΠ·ΠΈΠ³ΠΎΡΠ½ΠΎΠ³ΠΎ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° GG / GG Π³Π΅Π½Π° MMP1 (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠ° (OΠ ) β 2,23, 95%-Π½ΡΠΉ Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π» (ΠΠ) β 1,34β3,73), Π°Π»Π»Π΅Π»Ρ GG Π³Π΅Π½Π° MMP1 (OΠ β 2,27, 95%-Π½ΡΠΉ ΠΠ β 1,61β3,20), Π³Π΅ΡΠ΅ΡΠΎΠ·ΠΈΠ³ΠΎΡΠ½ΠΎΠ³ΠΎ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π‘ / Π’ Π³Π΅Π½Π° MMP9 (OΠ β 2,43, 95%-Π½ΡΠΉ ΠΠ β 1,37β4,31), Π³ΠΎΠΌΠΎΠ·ΠΈΠ³ΠΎΡΠ½ΠΎΠ³ΠΎ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π’ / Π’ Π³Π΅Π½Π° MMP9 (OΠ β 4,38, 95%-Π½ΡΠΉ ΠΠ β 1,12β20,00), Π°Π»Π»Π΅Π»Ρ Π’ Π³Π΅Π½Π° MMP9 (OΠ β 2,78, 95%-Π½ΡΠΉ ΠΠ β 1,74β4,46). ΠΡΠ΅ Π²ΡΡΠ΅ΠΏΠ΅ΡΠ΅ΡΠΈΡΠ»Π΅Π½Π½ΡΠ΅ Π°Π»Π»Π΅Π»ΠΈ ΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΡ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠ°ΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π»ΠΈΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΡΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ ΠΠ‘Π’. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠ°ΡΡΠΎΡΠΎΠΉ Π°Π»Π»Π΅Π»ΡΠ½ΡΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΡΠΌ Π‘Π, Π½Π΅ ΠΈΠΌΠ΅ΡΡΠΈΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΠ‘Π’, ΠΈ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΎΠ½Π½ΠΎΠΉ Π²ΡΠ±ΠΎΡΠΊΠΎΠΉ Π½Π΅ Π±ΡΠ»ΠΎ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ Π½ΠΈ Π΄Π»Ρ ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΠΎΠ³ΠΎ Π»ΠΎΠΊΡΡΠ° ΠΈΠ·ΡΡΠ°Π΅ΠΌΡΡ
Π³Π΅Π½ΠΎΠ²
Hunt for new phenomena using large jet multiplicities and missing transverse momentum with ATLAS in 4.7 fbβ1 of sβ=7TeV proton-proton collisions
Results are presented of a search for new particles decaying to large numbers of jets in association with missing transverse momentum, using 4.7 fbβ1 of pp collision data at sβ=7TeV collected by the ATLAS experiment at the Large Hadron Collider in 2011. The event selection requires missing transverse momentum, no isolated electrons or muons, and from β₯6 to β₯9 jets. No evidence is found for physics beyond the Standard Model. The results are interpreted in the context of a MSUGRA/CMSSM supersymmetric model, where, for large universal scalar mass m 0, gluino masses smaller than 840 GeV are excluded at the 95% confidence level, extending previously published limits. Within a simplified model containing only a gluino octet and a neutralino, gluino masses smaller than 870 GeV are similarly excluded for neutralino masses below 100 GeV
- β¦